As the impact of the coronavirus continues to unfold, it’s critical that we recognize the increased challenges and uncertainties facing people living with rare diseases like sarcoidosis. Sarcoidosis is a complex, multi-system inflammatory disease, most commonly seen in the lungs and lymph nodes. In people with sarcoidosis, the immune system overreacts, forming clumps of cells called granulomas that result in inflammation to the body’s tissues. When too many granulomas form on an organ, they may interfere with the organ’s function.1,2
Throughout April’s Sarcoidosis Awareness Month, the American Lung Association (ALA) and the Foundation for Sarcoidosis Research (FSR) have collaborated to provide opportunities for those affected by sarcoidosis to learn more about how they can protect their health. Mallinckrodt is proud to sponsor this awareness campaign and to share our commitment to improving outcomes among patients with sarcoidosis and other autoimmune diseases and critical conditions.
The ALA and the FSR have a variety of resources available for patients, caregivers and clinicians who are interested in sarcoidosis education and awareness. Both organizations are also committed to keeping patients informed about COVID-19 as more science-based evidence about the illness becomes known.
Patients and caregivers can access these resources at StopSarcoidosis.org and Lung.org/sarcoidosis. Registered nurses, respiratory therapists and counselors are also available for one-on-one support through the ALA’s HelpLine at 1-800-LUNGUSA or online chat at Lung.org/helpline.
In addition, Mallinckrodt has also created knowsarcoidosis.com, a comprehensive website to inform, educate, and empower those who have been affected by sarcoidosis.
Finally, we would like to take this opportunity to acknowledge the myriad of healthcare providers who care for sarcoidosis patients, especially the pulmonologists, intensivists, nursing professionals and others now facing the increased burden of caring for patients with COVID-19. Thank you for all you do!
- Judson MA. The clinical features of sarcoidosis: a comprehensive review. Clin Rev Allerg Immunol. 2015;49:63-78.
- Boughman 2016 Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc 2016;13:1244-1252.
Above are links to third-party websites or other third-party information (third-party content). The third-party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. All trademarks, service marks and logos appearing on this page [or site] are the property of their respective owners. Any rights not expressly granted herein are reserved.
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2020 Mallinckrodt. 04/20